{"id":451402,"date":"2021-03-04T16:44:42","date_gmt":"2021-03-04T21:44:42","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=451402"},"modified":"2021-03-04T16:44:42","modified_gmt":"2021-03-04T21:44:42","slug":"kempharm-to-present-at-the-33rd-annual-roth-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-present-at-the-33rd-annual-roth-conference\/","title":{"rendered":"KemPharm to Present at the 33rd Annual Roth Conference"},"content":{"rendered":"
\n

CELEBRATION, Fla., March 04, 2021 (GLOBE NEWSWIRE) — KemPharm, Inc.\u00a0(NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced\u00a0that Travis C. Mickle, Ph.D., President and CEO of KemPharm,\u00a0will\u00a0present at\u00a0the 33rd<\/sup> Annual Roth Conference being held virtually from March 15-17, 2021.\u00a0The presentation will be available on demand during the virtual event for all registered attendees.<\/p>\n

Details regarding KemPharm\u2019s presentations are as follows:<\/p>\n\n\n\n\n\n
\n Event:<\/strong>\n <\/td>\n\n \u202f<\/strong>\n <\/td>\n\n 33<\/strong>
\n
\n rd<\/strong>
\n <\/sup>
\n Annual Roth Conference<\/strong>\n <\/td>\n<\/tr>\n
\n Date:\u202f<\/strong>\n <\/td>\n\n \u202f<\/strong>\n <\/td>\nMonday, March 15, 2021 to Wednesday, March 17, 2021<\/td>\n<\/tr>\n
\n Time:<\/strong>\n <\/td>\n\u00a0<\/td>\nAvailable on Demand<\/td>\n<\/tr>\n
\n Registration:<\/strong>\n <\/td>\n\n \u202f<\/strong>\n <\/td>\n\n https:\/\/roth.meetmax.com\/sched\/event_70981\/conference_home.html<\/a>\n <\/td>\n<\/tr>\n<\/table>\n

During\u00a0the\u00a0pre-recorded virtual presentation, Dr. Mickle will\u00a0provide an overview of\u00a0KemPharm\u2019s corporate achievements and potential milestones, including the U.S. Food and Drug Administration\u2019s (FDA) recent approval of AZSTARYS\u2122 (formerly known as KP415), a once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years and older. AZSTARYS consists of serdexmethylphenidate (SDX), KemPharm\u2019s prodrug of d-methylphenidate (d-MPH), co-formulated with immediate-release d-MPH.<\/p>\n

The complete label for AZSTARYS, including prescribing information and important safety information, may be found at https:\/\/kempharm.com\/wp-content\/uploads\/2021\/03\/AZSTARYS-Master-Label-Final_20210302.pdf<\/a>.<\/p>\n

\n About KemPharm:<\/strong>\n <\/p>\n

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT\u00ae<\/sup> (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT\u00ae<\/sup> technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm\u2019s product portfolio is highlighted by AZSTARYS\u2122, an FDA-approved, once-daily treatment for attention deficit hyperactivity disorder (ADHD) which is based on serdexmethylphenidate, (SDX), KemPharm\u2019s prodrug of d-methylphenidate (d-MPH). KemPharm is also advancing several clinical development candidates, including KP484 for the treatment of ADHD and KP879 for the treatment of Stimulant Use Disorder (SUD). AZSTARYS, KP484, and KP879 are all based on SDX. In addition, KemPharm has received FDA approval for APADAZ\u00ae<\/sup>, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com<\/a> or connect with us on Twitter<\/a>, LinkedIn<\/a>, Facebook<\/a> and YouTube<\/a>.<\/p>\n

\n Caution Concerning Forward Looking Statements:<\/strong>\n <\/p>\n

This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation KemPharm\u2019s proposed development and commercial timelines, and can be identified by the use of words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cproject,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cpotential,\u201d \u201cshould,\u201d \u201ccontinue\u201d or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements include statements about the commercial launch of AZSTARYS, including the timing of launch, the regulatory milestone payment, and the potential clinical benefits of AZSTARYS. These forward-looking statements are based on information currently available to KemPharm and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning KemPharm\u2019s business are described in detail in the \u201cRisk Factors\u201d sections of KemPharm\u2019s Annual Report on Form 10-K for the year ended December 31, 2019, KemPharm\u2019s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and KemPharm\u2019s other filings with the Securities and Exchange Commission. KemPharm is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n

\n KemPharm Contacts:<\/strong>\n <\/p>\n

\n
\n Tiberend Strategic Advisors, Inc.<\/u>
\n <\/a>
\n
Jason Rando\/Maureen McEnroe, CFA
(212) 375-2665 \/ 2664
jrando@tiberend.com<\/u><\/a>
mmcenroe@tiberend.com<\/a><\/u><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

CELEBRATION, Fla., March 04, 2021 (GLOBE NEWSWIRE) — KemPharm, Inc.\u00a0(NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced\u00a0that Travis C. Mickle, Ph.D., President and CEO of KemPharm,\u00a0will\u00a0present at\u00a0the 33rd Annual Roth Conference being held virtually from March 15-17, 2021.\u00a0The presentation will be available on demand during the virtual event for all registered attendees. Details regarding KemPharm\u2019s presentations are as follows: Event: \u202f 33 rd Annual Roth Conference Date:\u202f \u202f Monday, March 15, 2021 to Wednesday, March 17, 2021 Time: \u00a0 Available on Demand Registration: \u202f https:\/\/roth.meetmax.com\/sched\/event_70981\/conference_home.html During\u00a0the\u00a0pre-recorded virtual presentation, Dr. Mickle will\u00a0provide an overview of\u00a0KemPharm\u2019s corporate achievements and potential milestones, including the U.S. Food and Drug Administration\u2019s (FDA) recent approval of AZSTARYS\u2122 … <\/p>\n

Continue reading “KemPharm to Present at the 33rd Annual Roth Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-451402","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nKemPharm to Present at the 33rd Annual Roth Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-present-at-the-33rd-annual-roth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KemPharm to Present at the 33rd Annual Roth Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CELEBRATION, Fla., March 04, 2021 (GLOBE NEWSWIRE) — KemPharm, Inc.\u00a0(NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced\u00a0that Travis C. Mickle, Ph.D., President and CEO of KemPharm,\u00a0will\u00a0present at\u00a0the 33rd Annual Roth Conference being held virtually from March 15-17, 2021.\u00a0The presentation will be available on demand during the virtual event for all registered attendees. Details regarding KemPharm\u2019s presentations are as follows: Event: \u202f 33 rd Annual Roth Conference Date:\u202f \u202f Monday, March 15, 2021 to Wednesday, March 17, 2021 Time: \u00a0 Available on Demand Registration: \u202f https:\/\/roth.meetmax.com\/sched\/event_70981\/conference_home.html During\u00a0the\u00a0pre-recorded virtual presentation, Dr. Mickle will\u00a0provide an overview of\u00a0KemPharm\u2019s corporate achievements and potential milestones, including the U.S. Food and Drug Administration\u2019s (FDA) recent approval of AZSTARYS\u2122 … Continue reading "KemPharm to Present at the 33rd Annual Roth Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-present-at-the-33rd-annual-roth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-04T21:44:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDkxMCM0MDQ5NzI1IzIwMTc3NTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-present-at-the-33rd-annual-roth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-present-at-the-33rd-annual-roth-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"KemPharm to Present at the 33rd Annual Roth Conference\",\"datePublished\":\"2021-03-04T21:44:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-present-at-the-33rd-annual-roth-conference\\\/\"},\"wordCount\":641,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-present-at-the-33rd-annual-roth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDkxMCM0MDQ5NzI1IzIwMTc3NTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-present-at-the-33rd-annual-roth-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-present-at-the-33rd-annual-roth-conference\\\/\",\"name\":\"KemPharm to Present at the 33rd Annual Roth Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-present-at-the-33rd-annual-roth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-present-at-the-33rd-annual-roth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDkxMCM0MDQ5NzI1IzIwMTc3NTc=\",\"datePublished\":\"2021-03-04T21:44:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-present-at-the-33rd-annual-roth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-present-at-the-33rd-annual-roth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-present-at-the-33rd-annual-roth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDkxMCM0MDQ5NzI1IzIwMTc3NTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDkxMCM0MDQ5NzI1IzIwMTc3NTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-present-at-the-33rd-annual-roth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KemPharm to Present at the 33rd Annual Roth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KemPharm to Present at the 33rd Annual Roth Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-present-at-the-33rd-annual-roth-conference\/","og_locale":"en_US","og_type":"article","og_title":"KemPharm to Present at the 33rd Annual Roth Conference - Market Newsdesk","og_description":"CELEBRATION, Fla., March 04, 2021 (GLOBE NEWSWIRE) — KemPharm, Inc.\u00a0(NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced\u00a0that Travis C. Mickle, Ph.D., President and CEO of KemPharm,\u00a0will\u00a0present at\u00a0the 33rd Annual Roth Conference being held virtually from March 15-17, 2021.\u00a0The presentation will be available on demand during the virtual event for all registered attendees. Details regarding KemPharm\u2019s presentations are as follows: Event: \u202f 33 rd Annual Roth Conference Date:\u202f \u202f Monday, March 15, 2021 to Wednesday, March 17, 2021 Time: \u00a0 Available on Demand Registration: \u202f https:\/\/roth.meetmax.com\/sched\/event_70981\/conference_home.html During\u00a0the\u00a0pre-recorded virtual presentation, Dr. Mickle will\u00a0provide an overview of\u00a0KemPharm\u2019s corporate achievements and potential milestones, including the U.S. Food and Drug Administration\u2019s (FDA) recent approval of AZSTARYS\u2122 … Continue reading \"KemPharm to Present at the 33rd Annual Roth Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-present-at-the-33rd-annual-roth-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-04T21:44:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDkxMCM0MDQ5NzI1IzIwMTc3NTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-present-at-the-33rd-annual-roth-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-present-at-the-33rd-annual-roth-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"KemPharm to Present at the 33rd Annual Roth Conference","datePublished":"2021-03-04T21:44:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-present-at-the-33rd-annual-roth-conference\/"},"wordCount":641,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-present-at-the-33rd-annual-roth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDkxMCM0MDQ5NzI1IzIwMTc3NTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-present-at-the-33rd-annual-roth-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-present-at-the-33rd-annual-roth-conference\/","name":"KemPharm to Present at the 33rd Annual Roth Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-present-at-the-33rd-annual-roth-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-present-at-the-33rd-annual-roth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDkxMCM0MDQ5NzI1IzIwMTc3NTc=","datePublished":"2021-03-04T21:44:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-present-at-the-33rd-annual-roth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-present-at-the-33rd-annual-roth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-present-at-the-33rd-annual-roth-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDkxMCM0MDQ5NzI1IzIwMTc3NTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDkxMCM0MDQ5NzI1IzIwMTc3NTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-present-at-the-33rd-annual-roth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"KemPharm to Present at the 33rd Annual Roth Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=451402"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451402\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=451402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=451402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=451402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}